Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

INTRODUCTION: Liver resection is the mainstay of curative-intent treatment for hepatocellular carcinoma (HCC), but the postoperative 5-year recurrence rate reaches 70%, and there are no adjuvant or neoadjuvant therapies recommended by major HCC guidelines that can reduce the risk of recurrence. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bo, Yue, Jinbo, Shi, Xuetao, Cui, Kai, Li, Lei, Zhang, Chengsheng, Sun, Pengfei, Zhong, Jingtao, Li, Zhongchao, Zhao, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486305/
https://www.ncbi.nlm.nih.gov/pubmed/36115673
http://dx.doi.org/10.1136/bmjopen-2022-060955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486305/
https://www.ncbi.nlm.nih.gov/pubmed/36115673
http://dx.doi.org/10.1136/bmjopen-2022-060955

Ejemplares similares